Study in Patients With Asthma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00215397

Enrollment

Registered

2005-09-22

Start date

Unknown

Completion date

2005-12-31

Last updated

2010-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, Formoterol, Fumarate

Brief summary

The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug.

Interventions

DRUGFormoterol Fumarate

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

5 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients with a history of asthma

Exclusion criteria

* Current asthma exacerbation or recent asthma exacerbation, requiring hospitalization * History of smoking * Debilitating systemic and/or life-threatening diseases.

Design outcomes

Primary

Measure	Time frame
The primary outcome variable is the measure of lung function.	—

Secondary

Measure	Time frame
Secondary outcomes include change in lung function, as well as in vital signs.	—
Physical exams, AE reporting, etc.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026